Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling

[1]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[2]  Marc Therrien,et al.  Cancer: A drug-resistant duo , 2011, Nature.

[3]  A. Eggermont,et al.  Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1 , 2011, Clinical Cancer Research.

[4]  S. Pfister,et al.  Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma , 2011, International journal of cancer.

[5]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[6]  C. Pritchard,et al.  Mechanisms of aneuploidy induction by RAS and RAF oncogenes. , 2011, American journal of cancer research.

[7]  S. Lacomme,et al.  BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis , 2011, Pathology.

[8]  C. Berens,et al.  A novel MCF-10A line allowing conditional oncogene expression in 3D culture , 2011, Cell Communication and Signaling.

[9]  K. Flaherty,et al.  BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.

[10]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[11]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[12]  Nils Blüthgen,et al.  Strong negative feedback from Erk to Raf confers robustness to MAPK signalling , 2011, Molecular systems biology.

[13]  Alma L. Burlingame,et al.  A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK , 2011, Nature.

[14]  D. Morrison,et al.  RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling , 2011, Current Biology.

[15]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Charles Swanton,et al.  Genetic prognostic and predictive markers in colorectal cancer , 2011, Nature Reviews Cancer.

[17]  David B Solit,et al.  Resistance to MEK Inhibitors: Should We Co-Target Upstream? , 2011, Science Signaling.

[18]  P. Edwards,et al.  Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.

[19]  U. Rapp,et al.  Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase* , 2011, The Journal of Biological Chemistry.

[20]  W. Kolch,et al.  Raf family kinases: old dogs have learned new tricks. , 2011, Genes & cancer.

[21]  Julian Downward,et al.  Targeting RAF: trials and tribulations , 2011, Nature Medicine.

[22]  N. Rosen,et al.  Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.

[23]  R. Oostendorp,et al.  Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 , 2011, Leukemia.

[24]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[25]  A. Aplin,et al.  Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells , 2011, Oncogene.

[26]  N. Rosen,et al.  Mutant BRAF melanomas--dependence and resistance. , 2011, Cancer cell.

[27]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[28]  D. Solit,et al.  Drug discovery: How melanomas bypass new therapy , 2010, Nature.

[29]  M. Baccarini,et al.  Partner exchange: protein-protein interactions in the Raf pathway. , 2010, Trends in biochemical sciences.

[30]  A. Iafrate,et al.  BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.

[31]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[32]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[33]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[34]  Karen Cichowski,et al.  Drug discovery: Inhibitors that activate , 2010, Nature.

[35]  C. Der,et al.  The raf inhibitor paradox: unexpected consequences of targeted drugs. , 2010, Cancer cell.

[36]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[37]  Ursula Klingmüller,et al.  Theoretical and experimental analysis links isoform- specific ERK signalling to cell fate decisions , 2009, Molecular systems biology.

[38]  D. Morrison,et al.  Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.

[39]  D. Tuveson,et al.  C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). , 2009, Molecular cell.

[40]  M. Watson,et al.  Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma , 2009, Neurology.

[41]  E. Oikonomou,et al.  BRAFV600E Efficient Transformation and Induction of Microsatellite Instability Versus KRASG12V Induction of Senescence Markers in Human Colon Cancer Cells , 2009 .

[42]  S. Hirohashi,et al.  Resequencing Analysis of the Human Tyrosine Kinase Gene Family in Pancreatic Cancer , 2009, Pancreas.

[43]  Marc Therrien,et al.  A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.

[44]  S. Feller,et al.  Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. , 2009, Cancer research.

[45]  D. Pearson,et al.  Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma , 2009, Oncogene.

[46]  K. Resing,et al.  Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. , 2009, Molecular cell.

[47]  M. Digilio,et al.  Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum , 2009, Human mutation.

[48]  C. Noelke,et al.  MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib , 2009, Molecular Cancer Therapeutics.

[49]  U. Rapp,et al.  Regulation of RAF Activity by 14-3-3 Proteins , 2009, Journal of Biological Chemistry.

[50]  A. Jaffe,et al.  Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis , 2008, The Journal of cell biology.

[51]  J. Hussain,et al.  CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. , 2008, Molecular cell.

[52]  R. Seruca,et al.  B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. , 2008, Gastroenterology.

[53]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[54]  D. Peeper,et al.  BRAFE600 in benign and malignant human tumours , 2008, Oncogene.

[55]  M. Therrien,et al.  KSR and CNK: two scaffolds regulating RAS-mediated RAF activation , 2007, Oncogene.

[56]  M. Reth,et al.  Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein , 2006, Oncogene.

[57]  M. Matsuda,et al.  The amino‐terminal B‐Raf‐specific region mediates calcium‐dependent homo‐ and hetero‐dimerization of Raf , 2006, The EMBO journal.

[58]  Pablo Rodriguez-Viciana,et al.  A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. , 2006, Molecular cell.

[59]  Pablo Rodriguez-Viciana,et al.  Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.

[60]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[61]  R. Hennekam,et al.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.

[62]  Alcino J. Silva,et al.  Forebrain‐specific knockout of B‐raf kinase leads to deficits in hippocampal long‐term potentiation, learning, and memory , 2006, Journal of neuroscience research.

[63]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[64]  M. Garnett,et al.  Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. , 2005, Cancer research.

[65]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[67]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[68]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[69]  R. Aebersold,et al.  Two-dimensional Blue Native/SDS Gel Electrophoresis of Multi-Protein Complexes from Whole Cellular Lysates , 2004, Molecular & Cellular Proteomics.

[70]  M. Reth,et al.  Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf , 2003, Oncogene.

[71]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[72]  M. Reth,et al.  Inducible gene deletion reveals different roles for B‐Raf and Raf‐1 in B‐cell antigen receptor signalling , 2002, The EMBO journal.

[73]  R. Marais,et al.  14-3-3 Antagonizes Ras-Mediated Raf-1 Recruitment to the Plasma Membrane To Maintain Signaling Fidelity , 2002, Molecular and Cellular Biology.

[74]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[75]  P. Khavari,et al.  Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation , 2002, Oncogene.

[76]  W. Kolch,et al.  Regulation of Raf‐1 activation and signalling by dephosphorylation , 2002, The EMBO journal.

[77]  K. Guan,et al.  Positive and negative regulation of Raf kinase activity and function by phosphorylation , 2001, The EMBO journal.

[78]  J. Hancock,et al.  Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions , 2001, Oncogene.

[79]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[80]  K. Guan,et al.  Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601 , 2000, The EMBO journal.

[81]  T. Barber,et al.  Negative regulation of the serine/threonine kinase B-Raf by Akt. , 2000, The Journal of biological chemistry.

[82]  W. Kolch,et al.  Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.

[83]  Anthony J. Muslin,et al.  Disruption of the 14-3-3 Binding Site within the B-Raf Kinase Domain Uncouples Catalytic Activity from PC12 Cell Differentiation* , 2000, The Journal of Biological Chemistry.

[84]  Giulio Superti‐Furga,et al.  Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.

[85]  A. Eychène,et al.  Modulation of Kinase Activity and Oncogenic Properties by Alternative Splicing Reveals a Novel Regulatory Mechanism for B-Raf* , 1998, The Journal of Biological Chemistry.

[86]  C. Marshall,et al.  Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.

[87]  Sally J. Leevers,et al.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane , 1994, Nature.

[88]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[89]  J. Cunningham,et al.  A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection , 1989, Cell.

[90]  G K Lewis,et al.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product , 1985, Molecular and cellular biology.

[91]  P. Seeburg,et al.  Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations , 1983, Nature.

[92]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .

[93]  Walter Kolch,et al.  Biology using engineering tools: The negative feedback amplifier , 2022 .